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Abstract-Use of continuous ambulatory peritoneal dialyses (CAPD) is increasing, and it is being 
promoted as a less expenstve alternative to center hemodialysis (CHD). The debate over the relative 
charges for CAPD and CHD cannot generally be answered wtthout considering the relationship 
between modality selection and patient characteristics. When selection and patient characteristics 
are accounted for. the difference between annual charges for CAPD and CHD patients IS 
insignificant, in part because of the current payment system. The analysis suggests that patients 
using CHD may have lower charges than if they were using CAPD; similarly, patients using CAPD 
may have lower charges than if they were using CHD. Charges during CAPD trainmg are lower 
than CHD or CAPD charges. Charges during the transition between CHD and CAPD tend to be 
higher than either CHD or CAPD due to additional hospitalizations. Estimated results suggest that 
encouraging current CHD patients to transfer to CAPD (or vice versa) may not havje the desired 
effect of reducing charges. 
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INTRODUCTION 
Since the introduction of continuous ambu- 
latory peritoneal dialyses (CAPD) in 1979. it has 
become a common alternative to center hemo- 
dialysis (CHD) and other modalities of treat- 
ment for end-stage renal disease (ESRD). CHD 
is still the treatment of choice for 80% of ESRD 
patients on dialysis. but the use of CAPD has 
been increasing and currently stands at over 
14% of ESRD patients on dialysis [I. 21. 
The rapid increase in the use of CAPD has 
prompted debates over the relative effectiveness 
and cost of CAPD vs other modalities of treat- 
ment, especially CHD [3-81. Some of the advan- 
tages of CAPD are reductions in anemia and 
hypertension and greater freedom of movement. 
But there are also the disadvantages of an 
increase in the risk of peritonitis and other 
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catheter complications and a reduction in op- 
portunities for medical supervision [9-l I]. The 
net effect of these advantages and disadvantages 
has not been fully determined, but it is thought 
to vary depending on the characteristics of the 
patient. 
Government reimbursement regulations at- 
tempt to encourage the use of CAPD, based on 
the belief that it is less costly than CHD [12]. 
Earlier studies have suggested that the cost of 
CAPD is somewhat less than the cost of CHD. 
but results have not been conclusive. Since the 
major disadvantage of CAPD is the risk 01’ 
catheter complications, which may require hos- 
pitalization many reports have focused on the 
relative use of inpatient hospital services. A 
higher number of hospitalizations for CAPD as 
compared to CHD patients was found by 
Bovbjerg et al. [3] and Carlson or al. [4]. How- 
ever, no stgnificant difference in the mean num- 
ber of hospitalizations between patients on these 
two modalities was found by Manninen et ul. [7] 
or Prowant rt ul. [8]. 
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Prowant et al. found hospital charges to be 
insignificantly lower for CAPD but found total 
charges to be significantly lower. However, this 
study included only 46 patients at one center 
and was unadjusted for patient characteristics. 
Evans et al. [5] found inpatient hospital reim- 
bursement to be lower and total reimbursement 
to be lower for CAPD as compared to CHD, 
after adjusting for patient characteristics, but 
these differences were insignificant. 
This paper reports on the relative Medicare 
allowable charges for CAPD and CHD for a 
sample of ESRD patients from the Michigan 
ESRD Study. This study examines ESRD 
charges in a more complex manner than have 
previous authors. The results are also more 
complex, but provide a more meaningful exam- 
ination of charges. Two important differences 
from the previously cited work are the more 
explicit definition of modality employed and the 
consideration of the effects of patient character- 
istics on the selection of modality. 
MATERIALS AND METHODS 
Data for this investigation come from the 
Health Care Financing Administration 
(HCFA), through the Urban Institute. Data 
for 1982-1984 were requested for all adult 
Michigan patients with onset of ESRD from 
1981-1983. The Urban Institute identified 
Michigan patients and prepared data sets from 
the various Medicare ESRD Program files. Five 
data sets were received, each corresponding to a 
different part of the Medicare data system. Four 
data sets, patient identification, medical evi- 
dence, transplant, and quarterly dialysis 
records, come from the ESRD Program Man- 
agement and Medical Information System 
(PMMIS). The fifth data set, containing charge 
data, comes from HCFA provider billing 
records. Matching data from all sources resulted 
in 2292 complete observations and a sample of 
1446 (65.3%) complete observations on patients 
with CAPD, CHD or a combination. The re- 
maining 796 observations pertain to patients 
with all other forms of treatment, including 
transplantation. All patients receiving tan- 
splants at any point in time were classified as 
transplant patients, irrespective of their use of 
CHD or CAPD during the study period. Hence, 
the analyses presented in this paper are based on 
all adult Michigan patients using CAPD or 
CHD about whom complete data are available 
for any amount of time within the 3-year study 
period. 
Charges 
Charges are measured as Medicare allowable 
charges. These are the charges which serve as 
the basis for Medicare payments to providers 
for services rendered. In simplest terms, Medi- 
care pays approximately 80% of allowable 
charges. Actual Medicare payments for dialysis 
services are based on predetermined fixed 
rates which are identical for CHD and CAPD 
patients. Prior to August 1983, renal physicians 
received monthly capitations under either the 
“initial method,” which varied payment by 
patient treatment location and allowed addi- 
tional fee-for-service charges, or the “alternative 
reimbursement method,” which paid a fixed 
monthly payment which also varied payment by 
patient treatment location. Since August 1983, 
physicians and facilities have been paid monthly 
capitation payments which are the same for 
CHD and CAPD patients. For both dialysis 
treatments and physician services, Medicare 
Part B payments are set at 80% of the pre- 
determined rates. Hospital payments are based 
on Medicare Part A allowable charges, which 
since 1983-1984 have been based on pre- 
determined rates by diagnosis-related group 
(DRG). Because the deductibles for both Parts 
A and B are small relative to total charges, the 
correlation between Medicare allowable charges 
and Medicare expenditures for ESRD patients 
is nearly perfect (r = 0.98) and Medicare ex- 
penditures are approximately 80% of total 
charges. In this analysis, total charges are used 
as the measure of charges. Total charges (100%) 
include payments made by Medicare (80%) and 
payments by, or on behalf of, the patient (20%) 
and are a reasonable estimate of total payments 
for Medicare covered services. 
Our measure of charges does not include 
payments made by the patient or on the pa- 
tient’s behalf for non-covered medical services 
or other expenses associated with the receipt of 
services. The use of home health aides and travel 
costs are examples of noncovered services and 
other expenses, respectively. For current policy 
purposes, it is perhaps most relevant to focus on 
payments for covered services, and in particular 
on Medicare allowable charges for services. For 
future policy changes, understanding the vari- 
ation in both total charges and total costs 
among treatment modalities would be useful. 
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To the extent that Medicare payment rules 
succeed in setting allowable charges (or their 
fixed reimbursements) close to the costs of 
production, our measure of charges is an ap- 
proximation of the production costs of ESRD 
treatment. Held and Pauly [I 31 have argued that 
because of the reimbursement rules and the 
incentives for competition on the basis of ame- 
nities, observed production costs are likely to 
exceed the minimum potential costs. The actual 
relationship between costs and charges has not 
been investigated and is an important area for 
future research. 
Selection 
The process of ESRD treatment is not typi- 
cally the selection and subsequent use of a 
single, well-defined modality. Usually. patients 
begin treatment with CHD and then either seek 
a transplant or consider alternative forms of 
dialysis. although selecting CAPD as the initial 
modality is becoming more common. Medicare 
payment rates are currently identical for CAPD 
and CHD. However. reimbursement begins in 
the first month of treatment for patients select- 
ing CAPD or CAPD training (and for trans- 
plant patients). and not until the third month 
after onset of ESRD for patients selecting 
CH D. Therefore, CAPD is being encouraged as 
an initial modality of treatment by the differ- 
ence in Medicare payments of approximately 
U.S. $6000. For patients already Medicare 
qualified or otherwise insured. this financial 
incentive is less important than for those 
patients without insurance. 
The definition of modality provided by Smith 
and Wheeler [I41 includes the “steady-state” 
(unchanged during the year) use of CHD and 
CAPD. “training” modalities and “transi- 
tional” modalities (changes during the year). All 
CAPD patients in this sample have spent some 
time in CAPD training (CAPDTR) and/or a 
combination of CAPD and CAPDTR (CAP- 
DCOMB), and some have spent time in a 
transitional stage between CHD and CAPD 
(CHD-CAPD). Most patients on CHD have 
not changed from other treatments. although 
some have changed from CAPD and have spent 
time in a transitional stage between CAPD and 
CHD (CAPDPCHD). 
The seletion of a particular modality, while 
not deterministic, is not completely random. 
Patients along with their physicians select that 
modality which is believed to be the most 
appropriate form of treatment, given their con- 
dition. No formal criteria have been followed 
for CHD and CAPD selection. as has been 
suggested for cancer patients by Simes [IS] and 
cadaver kidney recipients by Starzl c’t ul. [16]. 
but the data suggest systematic selection of 
modalities. Cost may or may not be a direct 
determinant of modality selection. but relative 
costs are influenced by the modality selection 
process. 
For example, suppose there were two 
patients. the younger with ESRD caused by, 
hypertenston and the older with ESRD caused 
by glomerulonephritis. While the younger 
patient might very well have lower costs using 
CAPD, the older might be prone to compli- 
cations or have difficulty with the process of 
performing the tasks associated with CAPD, 
and as a result have lower costs using CHD. 
One could not conclude that one type of 
treatment was less costly than the other unless 
patient characteristics and selection were 
included m the analysis. 
The characteristics of the patients observed in 
this study are presented in Table I. CHD and 
CAPD patients in this sample tend to be similar 
in age, gender and time since onset of ESRD, 
but patients on CAPD. in training. or in transi- 
Table I. Patient characteristics by modalit) 
Steady-state Traming Transltlon 
CH[) CAPD CAPDTR CAPCOMB CHD-CAPD -?APD CHD 
.- Age (jr) 5X.2 52.3* 55 5 50.5* 54.8 4x o* 
Sex (male) 46 5 57.x* 49.5 57.’ 44. I 37.5 
Race (white) S6 0 90.0* 8h.6f x9.1* XX.?’ 79.2’ 
Time since onset (yr) 7 0 IY 7.1 2.0 7.2 2.1 
Primary disease (4~) 
Diabetes 21.5 16.7 71.0 19.6 I I.8 ii.3 
Glomerulonephrltls 27 3 ‘6.7 33.9’ 34.x* 76.5 29.2 
tiypertension 33 I ‘I I 29.0 19.fI* 23.5 15.0 
Other ‘3 0 35.fl* 16.l* 26 I xi.?* II 5 
Observations I I06 90 IX6 46 34 74 
- 
*Indicates a ugnificant difference from steady-state CHD (first column). ,I < 0.05. two-talled teat. 
820 DEAN G. SMITH and JOHN R. C. WHEELER 
tion are much more likely to be white than CHD 
patients (p < 0.05). The porportion of non- 
whites on CAPD (10%) is lower than the pro- 
portion on CHD (44%) and is reflective of 
differences in treatments by race which have 
been frequently noted and criticized in the 
literature [17]. Reasons for the differences in 
modality by race in this sample are not ex- 
plainable on the basis of other available data on 
patient characteristics. 
Hypertension is the leading primary disease 
causing ESRD among CHD patients, with the 
other diseases being evenly distributed. Glomer- 
ulonephritis tends to be the leading primary 
disease causing ESRD among CAPD, training 
and transitional patients, although there are no 
clear patterns of primary diseases within these 
groups of patients. Comparing the incidence of 
primary diseases across modalities, there are 
some significant differences, particularly in the 
incidence of diabetes, but again, there are no 
clear patterns. 
Estimation 
To adjust for modality selection and 
differences in patient characteristics, a two-part 
estimation technique is employed. Failure to 
account for selection would result in biased 
estimates of charges by modality [ 181. In the first 
part, a self-selection probit model is estimated 
for each modality. Individual probit models for 
the selection of each modality are estimated 
using patient characteristics (age, sex, race, time 
since the onset of ESRD and primary disease) 
as determinants of selection. A potentially im- 
portant limitation of this study is the lack of 
additional patient and physician data which 
might more exactly determine selection. It has 
been shown that there are patterns of physician 
treatment recommendations which are indepen- 
dent of the above listed patient characteristics 
P91. 
The probit model estimations permit the cal- 
culation of an additional variable which, essen- 
tially, is an estimate of the likelihood that a 
particualr modality will be selected by a patient. 
The calculation of these variables uses the in- 
verse of the Mill’s ratio which takes the form, 
R, = 4(zijGi)/(@(zijGi), where R is the ratio for 
the ith individual using thejth modality, 4 and 
@ are the probability and cumulative density 
functions for the standard normal distribution, 
respectively, z is the matrix of independent 
variables and G is the vector of coefficients from 
the probit model estimations. 
In the second part, the variable calculated in 
the first part (R) is used as a covariate along 
with other patient characteristics (age, sex, race, 
primary disease causing ESRD, year of obser- 
vation and length of time observed) in a multi- 
variate ordinary least squares regression of the 
logarithm of annual charges. Logged charges 
are used to avoid the problems associated with 
extreme values which are frequently encoun- 
tered in health care charge data [20]. Obser- 
vations of charges of less than U.S. $500 for 
more than one quarter of a year and charges in 
excess of U.S. $200,000 are considered to be 
gross outliers and are not included in the final 
sample of 1496. Inclusion of these 78 outliers 
(5%) however, only affect the variances of final 
results and not the mean values. 
Standardized values of patient characteristics 
for each modality are used in the estimated 
equations to determine the charges of ESRD 
treatment by modality. This approach is de- 
scribed in general by Maddala [21] and in terms 
of specific examples in Heckman [18] and Lee 
[22]. The standardized value for length of time 
of observation is 12 months for all modalities. 
Although some observations are for periods of 
time less than a full year, in particular those for 
training and transition between modalities, all 
estimates are annualized. The estimates of train- 
ing and transition modalities must therefore be 
used with caution, as the charges associated 
with training and transition are actually for 
relatively short periods of time. 
Since charges are estimated in logs, estimated 
standard deviations are also in logs. Standard 
deviations are therefore log-linear rather than 
linear and simple confidence intervals are not 
meaningful. Instead, p-values of two-tailed tests 
are presented for comparisons among estimates 
of charges. 
The statistical analysis was conducted using 
the Michigan Interactive Data Analysis Systems 
(MIDAS), a program capable of handling the 
probit and multivariate least squares regression 
analyses required by this two-part technique. 
RESULTS 
Table 2 presents estimates of the costs of 
ESRD treatment by modality for patients with 
different characteristics. The columns reflect the 
estimated charges of patients with those charac- 
teristics. For example, under the column labeled 
“CHD,” the entries indicate the estimate of 
what the charges would be for patients similar 
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‘Table 2. Estimated treatment charges by modality and 








27.344 23.344 22.688 




I X.O?9’ 15.232*t 12.30g*t 
I7.360* I?.h64*’ 11.316*1- 
CHD CAPD 25.982 43,X26*t 30.094*t 
CAPD CHD 30.773 32,415* 26.792 
*Indicates a sigmficant difference from steady-state CHD 
(first row), p i 0.05, two-tailed test. 
tlndicates a signlticant dllrerence from steady-state CAPD 
(second roti). p < 0.05. tHo-talled teat. 
to those currently on CHD if they were treated 
using each of the six modalities. Correspond- 
ingly. the rows reflect the estimated charges for 
treatment by each modality: for patients actu- 
ally receiving that treatment. and for patients 
with the characteristics of those receiving CHD 
and CAPD. This table could be “completed” by 
listing additional columns for each of the train- 
ing and transitional modalities. Only the steady- 
state use of CHD and CAPD are listed since a 
patient is not trained or in transition for a long 
period. 
Patients with CAPD characteristics using 
CAPD have lower average annual charges than 
patients with CHD characteristics using CHD. 
Although the difference is not significant 
(p = 0.28), it is consistent with the observation 
that CAPD is less expensive than CHD. How- 
ever. while it may be less expensive to treat 
patients with CAPD characteristics using 
CAPD. it is not necessarily less expensive to 
treat patients with other characteristics using 
CAPD. 
Patients with (‘HD characteristics incur 
charges averaging U.S. $23,344 using CHD. 
Estimated charges for these same CHD patients 
and U.S. $25.915 if they were using CAPD. 
This difference is not statistically significant 
(p = 0.19), but it suggests an appropriate selec- 
tion of CHD patients in the use of CHD. 
Patients with CAPD characteristics generate 
charges of U.S. $21.429 using CAPD. Estimated 
charges for these same CAPD patients are 
U.S. $22.688 using CHD. Once again this 
difference is not significant (p = 0.47). but it 
indicates an appropriate selection of CAPD 
patients in the use of CAPD. 
Actual and estimated charges for all patients 
using the training for CAPD are significantly 
lower than the steady-state use of either CHD 
or CAPD. On the other hand. annualized 
charges during transition from CHD to CAPD 
and from CAPD to CHD are higher than the 
steady-state use of either CHD or CAPD. AC- 
tual transition charges, the charges for those 
patients actually making a change of modality, 
are higher going from CAPD to CHD than 
from CHD to CAPD. Estimated charges for 
CHD and CAPD patients are higher going from 
CHD to CAPD than from CAPD to CHD. This 
seemingly paradoxical result is discussed in the 
next section. 
Not unexpectedly, different variables are 
important in determing the likelihood of the 
selection and the costs of different modalities. 
(Tables of probit and ordinary least squares 
regressions are not presented. but are available 
from the authors upon request.) Age and race 
are consistently significant in the selection of 
modalities of treatment, but are infrequent11 
significant in the determination of charges. Year 
of observation and length of time observed are 
significant factors in the determination of 
changes in charges over time, but not oi 
differences in charges across modalities. Race. 
time since the onset of ESRD, and primary 
disease ca.using ESRD are only occasionall) 
significant factors in determining differences in 
charges across modalities. 
While there were several changes in the 
ESRD payment system and specific rates during 
the study period, including the introduction of 
prospective payment for hospitalizations, the 
relationships described in Table 2 did not vary 
significantly or substantively using estimates o! 
each year individually. Any effects on relative 
charges due to changes in the payment system 
were not observed. 
Some variables which might be significant 
factors in determining selection and/or charges. 
such as complications, secondary illnesses and 
facility type. are not available in these data. The 
addition of more data on patient characteristics 
would certainly increase the validity of the 
reported results. Without additional data the 
results presented below must be considered 
preliminary. 
The relative charges of CAPD and CHD are 
examined using a more explicit definition of 
822 DEAN G. SMITH and JOHN R. C. WHEELER 
modality, statistical correction for modality 
selection and statewise data from the Michigan 
ESRD Study. The estimated difference between 
annualized charges for CHD and CAPD pa- 
tients is positive, but insignificant. When selec- 
tion and patient characteristics are considered, 
estimated charges suggests that, in terms of 
charges, patients appropriately select modalites. 
On the basis of this result, a general shift of 
patients from CHD to CAPD or vice versa 
would be unlikely to reduce Medicare allowable 
charges. 
Although this analysis more completely 
examines costs than previous studies, the simple 
differences in adjusted CHD and CAPD costs 
are not the end of the comparison. The use of 
CAPD also implies the use of CAPDTR and 
perhaps CAPDCOMP, CHDCAPD and/or 
CAPDCHD, and several patients changed 
from one modality to the other. Therefore, the 
full charge for changing modality must take into 
account the charges incurred with the period of 
change. The importance of the annualized 
charges for training and transition, however, 
should not be exaggerated. The periods of time 
in training or in a transitional stage between 
modalities are typically quite short (a few weeks 
at most) and do not greatly influence 
charges over long period of time. 
total 
The periods of time on CAPDTR and 
CAPDCOMP are typically associated with 
lower costs than either CHD or CAPD. This 
result is contrary to expectations since there are 
start-up costs associated with training and 
changing modalities. However, patients typi- 
cally elect to begin training when their condi- 
tions are stable and their health is otherwise 
good. The lack of other adverse health condi- 
tions and the careful supervision during training 
result in lower charges. However, it is not the 
case that patients could elect to be trained 
permanently as a way to minimize charges. 
The switching of modalities other than 
through training is associated with higher 
charges for both CAPD and CHD patients. The 
result that actual charges are higher for the 
CAPDCHD transition than for the CHD- 
CAPD transition was expected. Complications 
with CAPD and the possibility of failure of this 
modality have been noted in the literature. The 
result that estimated charges are higher for the 
CHD-CAPD transition than for the 
CAPD-CHD transition for both CHD and 
CAPD patients is somewhat paradoxical. The 
reason for this result is that the patients actually 
making the transitions differed in terms of their 
characteristics from the average CHD and 
CAPD patients. The most important of these 
characteristics is the presence of diabetes as the 
primary disease causing ESRD. Diabetics with 
ESRD have average charges which are higher 
than non-diabetics. Since the actual transition 
charge estimates for CHDCAPD and 
CAPDCHD have as a basis rates of diabetes of 
11.8 and 33.3%, respectively, CAPDCHD 
tends to be associated with higher charges. The 
standardization of the rates of diabetes at 21.5 
and 16.7% for CHD and CAPD, respectively, is 
the cause of the reversal in estimated charges. 
This result should be taken with caution since it 
is based on relatively small numbers of patients 
making transitions. 
Transition period in this sample were also 
frequently associated with a hospitalization, in- 
dicating perhaps that a change of modality was 
required because of the failure of a course of 
treatment. Only 4 of the 58 patients making 
transitions (2 in each direction) did not have an 
episode of hospitalization. Voluntary transfers 
may very well not result in higher charges. The 
reason for changing modality (required vs vol- 
untary) is not available and should be explored 
in future investigations. 
The number of hospitalizations for patients 
on each modality using their actual character- 
istics are shown in Table 3. The differences 
between the steady-state use of a modality and 
training are small and insignificant. However, 
the transitions are associated with an average of 
one more admission, and the differences for 
noted combinations are significant (p < 0.05). 
No data were available on hopsital days. 
Table 3. Hospital admissions by 
modality 
Modality Mean SD 
Steady-state 
CHD 1.16 (1.59) 
CAPD 1.36 (1.29) 
Training 
CAPDTR 1.23 (1.40) 
CAPDCOMB 1.07 (1.41) 
Transition 
CHDCAPD 2.OOt (1.84) 
CAPD-CHD 2.42’t (2.04) 
*Indicates a significant difference 
from steady-state CHD (first row), 
p i 0.05, two-tailed test. 
TIndicates a significant difference from 
CAPD, CAPDTR and CAPDCOMB 
(second, third and fourth rows), 
p i 0.05, two-tailed test. 
The difference between these hospitalization 
results and those of previous authors is most 
likely accounted for by the difference in the 
definition of modality. Other studies have 
not separated steady-stated use of well-defined 
modalities from training and transitional 
period. Since it is the transitional modalities 
which tend to have greater than the average 
number of admissions, the modality in which 
these transitions are included, CHD or CAPD. 
will be observed to have the higher rate of 
hospitalization. 
A major result of this paper. that Medicare 
allowable charges for CHD and CAPD are very 
similar, can be largely attributed to the Medi- 
care ESRD payment system which in recent 
years has established similar facility and physi- 
cian reimbursement rates for CHD and CAPD. 
The principal conclusion of this paper must 
therefore be restated. It is that. given the current 
payment system. a shifting of patients from 
CHD to CAPD (or vice versa) is unlikely to 
result in a reduction in changes or Medicare 
expenditures. What we do not know is whether 
such shifts are likely to reduce the treatment 
costs to the provider. Research on this question 
needs to be done. But we argue strongly that 
this research must employ methods described in 
this paper; i.e. research on the relative costliness 
of ESRD modalities must account for the effects 
of patient characteristics on modality selection 
and costs. 
The current Medicare ESRD payment system 
is based on the assumption that CAPD costs are 
lower than CHD costs. Equal payments for 
CHD and CAPD are intended to give providers 
more profit from the presumably less costly 
CAPD and therefore to encourage a shift from 
CHD to CAPD. We believe that this policy is 
flawed in two respects. First, it is not based on 
a knowledge of the relative costs of modalities 
for particular patients. Second, the setting of 
equal prices for the two modalities means that 
any cost savings associated with a shift to 
CAPD are fully appropriated by the providers; 
the government and the patient do not benefit 
at all. 
If it can be determined that. for patients with 
particular characteristics. one modality is less 
costly than the other. then the government 
should reconsider its payment system. Stronger 
incentives for the use of the most appropriate 
and least costly modality should be instituted. 
Such an incentive system might involve con- 
tinuing the current physician payment system. 
which pays the same capitation for both CHD 
and CAPD, but altering the facility payment 
system to reflect the relative production costs. 
Such a system might leave the physician 
financially indifferent, but give the patient the 
incentive via the 20% coinsurance rate. to deter- 
mine the least costly modality. 
Finally. the scientifically most appropriate 
way to compare costs and control for patient 
characteristics and selection is to conduct a 
prospective study which randomly assigns 
patients to modalities of treatment. However. 
such an experiment is clinically inappropriate if 
modalities are indeed selected so as to maximize 
health outcomes which depend on patient 
characteristics. If so. statistical controls must 
be relied on. The statistical adjustment for 
patient selection of modalities presented in this 
paper represents an improvement over previous 
studies comparing various ESRD treatment 
modalities. 
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